Table 4.
Spontaneous resolution of adnexal masses observed during follow-up.
| Adnexal Masses with Spontaneous Resolution, (n = 94, 16.4%) | ||
|---|---|---|
| Patient Group (Total Number of Masses, Percentage) |
Premenopausal Women (n = 73, 80.2%) |
Postmenopausal Women (n = 21, 23.1%) |
| Diameter of the lesion (mm) | ||
| Range | 31–119 | 34–67 |
| Median (± SD) | 45.6 ± 16.4 | 42.3 ± 12.3 |
| Time interval to resolution (months) (median ± SD) | ||
| Median ± SD | 11 ± 10 | 18.6 ± 10 |
| In the first year of follow-up | 41 (56.2%) | 5 (23.8%) |
| Tumour type using IOTA terminology | ||
| Unilocular | 42 (57.5%) | 6 (33.3%) |
| Unilocular—solid | - | - |
| Multilocular | 30 (41.1%) | 15 (83.3%) |
| Multilocular—solid | - | - |
| Solid | - | - |
| Ultrasound examiner’s subjective assessment | ||
| Simple, para-ovarian or salpingeal cyst | 23 (31.5%) | 3 (14.3%) |
| Serous cystadenoma | 17 (23.3%) | 6 (28.6%) |
| Mucinous cystadenoma | 1 (1.4%) | - |
| Endometrioma | 10 (13.7%) | 2 (9.5%) |
| Teratoma | - | - |
| Hydrosalpinx or salpingitis | 15 (20.5%) | 9 (42.9%) |
| Abscess, salpingitis or pelvic inflammatory disease | 4 (5.5%) | - |
| Inclusion or peritoneal cyst | - | 1 |
| Serous cystadenofibroma | - | - |
| Not possible to define | 3 (4.1%) | - |